The disruption of alcohol use (AUD) is a devastating disease determined by a period of drinking and severe withdrawals, often causing chronic relapse courses. Initially, alcohol was consumed for the effects of positive reinforcement, but the stages of AUD were then marked by drinking to reduce the negative emotional state induced withdrawal. The brain stress response system in Extended Amygdala is recruited with excessive alcohol intake, sensitive with recurring withdrawals, and contributes to addiction development.
In this study, we investigated one of the brain stress response systems, polypeptides of the pituitary clasp (Pacip), and the receptor of Serumpun, PAC1R, in the behavior induced by alcohol. During acute withdrawal, mice exposed to chronic intermittent ethanol steam (ethanol dependent) display a significant increase in the level of PACP in the nucleus bed of the terminal stria (BNST), the brain area in repetition of Amygdala involved critically in stress and withdrawal.
There were no changes to the Level of Pacap observed at the central core of Amygdala. The specific microinfusion of the site of PAC1R PACAP antagonists (6-38) into the dose of BNST-Department blocks excessive alcohol intake in mice that depend on ethanol without affecting overall water intake or basal ethanol intake in control, nondependent mice. Intra-BNST PACAP (6-38) also reverses behavior such as anxiety caused by ethanol in mice that depend on ethanol, but does not affect this size in mouse control. Our findings show that chronic chronic ethanol exposure recruits the PACAP / PAC1R system from BNST and that this neuroaptasi mediates alcohol drinking behavior and such anxiety observed during withdrawal, indicating that this system represents the main brain stress element responsible for the negative reinforcement associated with ” The dark side is “alcoholism.
The modified circadian activity and rhythmic rhythm / wake in a stable tube only polypeptide (stop) null mouse schizophrenia model
Sleep disorders and circadian rhythm generally occur in individuals with schizophrenia. The stable tubules are only polypeptides (ko) showing damage to behavior resembling symptoms of schizophrenia. We previously reported that stopping the mouse to bed slept less and had a more fragmented sleep and woke up rather than a wild type Litter friend under the light / dark cycle (LD) (Proft et al., Schizoph Bull. 2016; 42 (5): 1207-1215 ): 1207-1215). Here, we assess the phenotype of male circadian stops KO mice by examining the rhythm of the activity operating wheel and the purpose of sleep / wake EEG / EGS which is defined under the conditions of LD and Darkness (DD). The rhythm of activity operates wheels in KO and wild type mice is also heard in LD, and has a similar running period in DD. The shift in postponing phase in response to light pulses given at the beginning of the active phase below DD is preserved in KO mice.
KO mice have far lower activity levels, lower amplitude activity rhythms, less stable activities, and more fragmented activities than wild type mice in both lighting conditions. Ko Mice also spends more time and less time in the movement of fast eye movement (REMS) and non-REMS (NREMS) in LD and DD conditions, with a decrease in NREMS concentrated in the active phase. KO MICE also shows a changeful EEG feature and a higher rhythm of amplitude in Wake and Nrem (but not brakes) in both lighting conditions, with longer running periods in DD, compared to wild type mice. These results indicate that zero mutations stop in mice change the rules of sleep physiology / wake up expression of activity rhythms, but not roughly interfere with circadian mechanisms.
Pregnancy is inadequate by severely hypercholaneemia refractories from sodium taurocholate co-transportation of polypeptide deficiency
Sodium Taurochole transports polypeptide deficiency is the condition of a rare metabolic autosomic recessive condition which results in plasma bile acid levels that increase critically. Hypercholanaemia in similar conditions such as intrahepatic pregnancy cholestasis has been associated with an increased risk of midwifery results including birth birth.
We present the first case of the Sodium Taurocholate polypeptide deficiency in the current pregnancy in patients with one previously dead birth in the context of severe hypercolanaemia, where conventional care for cholestasis including urshodoxicolic acid, rifampicin and cholestyramine is not effective. Terapeutic plasma exchanges and new treatment with elobixibly tried with diverse results. Pregnancy produces premature premature delivery of a baby living at a gestation of 32 weeks.
Hydrophilic interactions dominate reverse temperature dependence on polypeptide hydration-free energy associated with hydrophobicity
We overcome the association of hydrophobic driving forces in folding protein with reverse temperature dependence on protein hydration, where stabilizing the effects of hydration strengthens with increasing physiological temperatures in the physiological range. Calculation of all atoms from free energy free energy conformer deca-alanine, holistically including backbone interaction and side chains together, indicating that interesting peptidide solvent interactions and thermal expansion solvents dominate the upside signature temperature that has been interpreted traditionally as hydrophobic stabilization Protein in aqueous solution.
IRF4 Peptide |
|||
MBS151926-005mg | MyBiosource | 0.05mg | EUR 175 |
IRF4 Peptide |
|||
MBS151926-5x005mg | MyBiosource | 5x0.05mg | EUR 770 |
IRF4 Blocking Peptide |
|||
20-abx062142 | Abbexa |
|
|
IRF4 Blocking Peptide |
|||
DF6198-BP | Affbiotech | 1mg | EUR 234 |
IRF4 Blocking Peptide |
|||
AF0692-BP | Affbiotech | 1mg | EUR 234 |
IRF4 Blocking Peptide |
|||
AF4776-BP | Affbiotech | 1mg | EUR 234 |
IRF4 Blocking Peptide |
|||
MBS428901-01mg | MyBiosource | 0.1mg | EUR 230 |
IRF4 Blocking Peptide |
|||
MBS8209654-1mg | MyBiosource | 1mg | EUR 190 |
IRF4 Blocking Peptide |
|||
MBS8209654-5mg | MyBiosource | 5mg | EUR 345 |
IRF4 Blocking Peptide |
|||
MBS8209654-5x5mg | MyBiosource | 5x5mg | EUR 1465 |
IRF4 Blocking Peptide |
|||
MBS9625574-1mg | MyBiosource | 1mg | EUR 380 |
IRF4 Blocking Peptide |
|||
MBS9625574-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
IRF4 Blocking Peptide |
|||
MBS9616765-1mg | MyBiosource | 1mg | EUR 380 |
IRF4 Blocking Peptide |
|||
MBS9616765-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
IRF4 Blocking Peptide |
|||
MBS9615069-1mg | MyBiosource | 1mg | EUR 380 |
IRF4 Blocking Peptide |
|||
MBS9615069-5x1mg | MyBiosource | 5x1mg | EUR 1650 |
IRF4 Immunizing Peptide |
|||
MBS427645-01mg | MyBiosource | 0.1mg | EUR 225 |
IRF4 Peptide - middle region |
|||
MBS3228901-01mg | MyBiosource | 0.1mg | EUR 180 |
IRF4 Peptide - middle region |
|||
MBS3228901-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
AAP32669-100UG - IRF4 Peptide |
|||
AAP32669-100UG | Aviva Systems Biology | 100ug | EUR 99 |
AAP38154-100UG - IRF4 Peptide |
|||
AAP38154-100UG | Aviva Systems Biology | 100ug | EUR 99 |
IRF4 Peptide - N-terminal region |
|||
MBS3248213-01mg | MyBiosource | 0.1mg | EUR 180 |
IRF4 Peptide - N-terminal region |
|||
MBS3248213-5x01mg | MyBiosource | 5x0.1mg | EUR 730 |
Mast Cell-Degranulating Peptide (MCD Peptide) / Peptide 401 |
|||
004-04 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
IRF4 Antibody (Center) Blocking peptide |
|||
MBS9219288-INQUIRE | MyBiosource | INQUIRE | Ask for price |
AAP38155-100UG - IRF4 Peptide - middle region |
|||
AAP38155-100UG | Aviva Systems Biology | 100ug | EUR 99 |
Peptide T |
|||
057-01 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FGL Peptide |
|||
073-36 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
APK peptide |
|||
076-81 | PHOENIX PEPTIDE | 200 μg | EUR 199.8 |
NEF peptide |
|||
076-83 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
SHA peptide |
|||
076-84 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
YSY peptide |
|||
076-86 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Peptide E / 3200-Dalton Adrenal Enkephalin-Containing Peptide (Bovine) |
|||
024-57 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
PSTAIR Peptide |
|||
070-61 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide |
|||
040-69 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Adjuvant Peptide |
|||
070-05 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Peptide-epsilon |
|||
058-22 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
Delicious Peptide |
|||
070-21 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
proSex peptide (20-55) |
|||
040-30 | PHOENIX PEPTIDE | 100 μg | EUR 355.32 |
proSex peptide (28-55) |
|||
040-31 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
proSex peptide (40-55) |
|||
040-32 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Bombinin-Like Peptide 1 amide / prepro-Bombinin-Like Peptide (44-70) amide / prepro-Bombinin-Like Peptide (107-133) amide |
|||
007-60 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Peptide F-9 |
|||
038-06 | PHOENIX PEPTIDE | 200 μg | EUR 58.32 |
Sturgeon Peptide (137-158) |
|||
021-94 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
NGR Peptide 1 |
|||
025-74 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Peptide Lv (Rat) |
|||
008-73 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Anorexigenic Peptide |
|||
070-10 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
GnRH Associated Peptide (GAP) (1-13) / GnRH Precursor Peptide (14-26) (Human) |
|||
029-03 | PHOENIX PEPTIDE | 500 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-24) / GnRH Precursor Peptide (14-37) (Human) |
|||
029-04 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
GnRH Associated Peptide (GAP) (1-53) / GnRH Precursor Peptide (14-66) (Human) |
|||
029-05 | PHOENIX PEPTIDE | 20 μg | EUR 267.84 |
GnRH Associated Peptide (GAP) (25-53) / GnRH Precursor Peptide (38-66) (Human) |
|||
029-06 | PHOENIX PEPTIDE | 100 μg | EUR 114.48 |
Bid BH3 peptide |
|||
025-87 | PHOENIX PEPTIDE | 1 mg | EUR 170.64 |
AF-16 Peptide |
|||
033-44 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide Lv (Human) |
|||
008-71 | PHOENIX PEPTIDE | 100 μg | EUR 405 |
Peptide Lv (Mouse) |
|||
008-72 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
GnRH Associated Peptide (GAP) (1-13) / Gn-RH Precursor Peptide (14-26) (Rat) |
|||
029-08 | PHOENIX PEPTIDE | 200 μg | EUR 64.8 |
ExE peptide M3mP6 |
|||
064-33 | PHOENIX PEPTIDE | 200 μg | EUR 244.08 |
Peptide B (Bovine) |
|||
024-56 | PHOENIX PEPTIDE | 200 μg | EUR 81 |
Peptide F (Bovine) |
|||
024-58 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
PLP Peptide (103-116) (Bovine) |
|||
070-14 | PHOENIX PEPTIDE | 5 mg | EUR 140.4 |
FMRF-Like Peptide |
|||
047-32 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Joining Peptide (Rat) |
|||
047-91 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Growth Hormone-Releasing Peptide-Related Peptide-1 (fGRP-RP-1) (Frog) |
|||
048-80 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Growth Hormone-Releasing Peptide-Related Peptide-2 (fGRP-RP-2) (Frog) |
|||
048-81 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Growth Hormone-Releasing Peptide-Related Peptide-3 (fGRP-RP-3) (Frog) |
|||
048-82 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Peptide T (4-8) |
|||
057-04 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Peptide T (5-8) |
|||
057-05 | PHOENIX PEPTIDE | 500 μg | EUR 64.8 |
Vasonatrin Peptide (VNP) |
|||
005-47 | PHOENIX PEPTIDE | 200 μg | EUR 214.92 |
Opioid Peptide Library |
|||
L-002 | PHOENIX PEPTIDE | 58 peptides | EUR 2691.36 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) |
|||
064-01 | PHOENIX PEPTIDE | 200 μg | EUR 108 |
PGMtide Control Peptide |
|||
040-70 | PHOENIX PEPTIDE | 100 μg | EUR 316.44 |
Growth Blocking Peptide |
|||
046-92 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Neuron Specific Peptide |
|||
047-55 | PHOENIX PEPTIDE | 200 μg | EUR 140.4 |
Heparin Binding Peptide |
|||
025-47 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Gastrin Related Peptide |
|||
027-09 | PHOENIX PEPTIDE | 5 mg | EUR 73.44 |
Obesity Peptide Library |
|||
L-003 | PHOENIX PEPTIDE | 160 peptides | EUR 7267.32 |
[D-Ala1]-Peptide T |
|||
057-02 | PHOENIX PEPTIDE | 5 mg | EUR 282.96 |
Peptide YY (PYY) (Human) |
|||
059-01 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Eledoisin Related Peptide |
|||
046-04 | PHOENIX PEPTIDE | 5 mg | EUR 58.32 |
proSex peptide (28-55) - EIA Kit |
|||
EK-040-31 | PHOENIX PEPTIDE | 96 wells | EUR 603.72 |
Peptide F 1 (Lobster) |
|||
047-62 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Phosphate Acceptor Peptide |
|||
058-24 | PHOENIX PEPTIDE | 500 μg | EUR 73.44 |
Morphine Tolerance Peptide |
|||
050-13 | PHOENIX PEPTIDE | 1 mg | EUR 102.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) |
|||
064-07 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia brasiliana) |
|||
047-39 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia brasiliana) |
|||
047-40 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
Peptide I / pro-Histine-Rich Basic Peptide (HRBP) (1-26) (Aplysia californica) |
|||
047-42 | PHOENIX PEPTIDE | 200 μg | EUR 444.96 |
Peptide II / pro-Histine-Rich Basic Peptide (HRBP) (29-40) (Aplysia californica) |
|||
047-43 | PHOENIX PEPTIDE | 500 μg | EUR 214.92 |
FGL Peptide - Cy3 Labeled |
|||
FC3-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 672.84 |
FGL Peptide - Cy5 Labeled |
|||
FC5-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 756 |
FGL Peptide - FAM Labeled |
|||
FG-073-36A | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Pedal Peptide (Pep) (Aplysia) |
|||
047-61 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
ExE peptide M3mP6 mutant |
|||
064-35 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
ExE peptide M3mP6 mutant |
|||
064-37 | PHOENIX PEPTIDE | 200ug | EUR 234.36 |
AF-16 Peptide - Antibody |
|||
H-033-44 | PHOENIX PEPTIDE | 100 μl | EUR 336.96 |
FGL Peptide - FITC Labeled |
|||
FG-073-36B | PHOENIX PEPTIDE | 1 nmol | EUR 405 |
Schizophrenia Related Peptide |
|||
047-79 | PHOENIX PEPTIDE | 5 mg | EUR 44.28 |
Insulin B (22-25) Peptide |
|||
035-08 | PHOENIX PEPTIDE | 5 mg | EUR 86.4 |
Eosinophilotactic Peptide (AGSE) |
|||
070-28 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Eosinophilotactic Peptide (VGSE) |
|||
070-29 | PHOENIX PEPTIDE | 5 mg | EUR 27 |
Cell Penetrating ARF Peptide (26-44) |
|||
068-56 | PHOENIX PEPTIDE | 500 μg | EUR 640.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - RIA Kit |
|||
RK-064-01 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
FGL Peptide - Biotin Labeled |
|||
B-073-36 | PHOENIX PEPTIDE | 20 μg | EUR 405 |
Peptide F (Bovine) - Antibody |
|||
H-024-58 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
Brain Peptide (Bees) Library |
|||
L-007 | PHOENIX PEPTIDE | 51 peptides | EUR 6456.24 |
Gastrointestinal Peptide Library |
|||
L-006 | PHOENIX PEPTIDE | 200 peptides | EUR 7267.32 |
Peptide R / CXCR4 Antagonist |
|||
030-25 | PHOENIX PEPTIDE | 200 μg | EUR 203.04 |
PGMtide Peptide - Cy3 Labeled |
|||
FC3-040-69 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Peptide - FAM Labeled |
|||
FG-040-69A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
[D-Arg14, D-Arg15]-MGF Peptide amide / C-terminal peptide of IGF-1 Ec amide |
|||
033-34 | PHOENIX PEPTIDE | 100 μg | EUR 177.12 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Antibody |
|||
H-064-07 | PHOENIX PEPTIDE | 50 μl | EUR 238.68 |
[D-Ala1]-Peptide T amide |
|||
057-03 | PHOENIX PEPTIDE | 500 μg | EUR 140.4 |
Peptide F (Bovine) - RIA Kit |
|||
RK-024-58 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Calmodulin Binding Peptide 1 |
|||
070-17 | PHOENIX PEPTIDE | 20 μg | EUR 214.92 |
Catch-Relaxing Peptide (CARP) |
|||
047-20 | PHOENIX PEPTIDE | 1 mg | EUR 199.8 |
FGL Peptide - Rhodamine Labeled |
|||
FR-073-36 | PHOENIX PEPTIDE | 1 nmol | EUR 537.84 |
Peptide-Depleted Plasma (Rat) |
|||
MB-099-02 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - RIA Kit |
|||
RK-064-07 | PHOENIX PEPTIDE | 125 tubes | EUR 932.04 |
Glycogenolysis-Inhibiting Peptide |
|||
023-63 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Anti-Inflammatory Peptide 1 |
|||
004-01 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 2 |
|||
004-02 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Anti-Inflammatory Peptide 3 |
|||
004-03 | PHOENIX PEPTIDE | 200 μg | EUR 27 |
Urokinase-Derived Peptide A6 |
|||
025-12 | PHOENIX PEPTIDE | 500 μg | EUR 129.6 |
PGMtide Peptide - Biotin Labeled |
|||
B-040-69 | PHOENIX PEPTIDE | 20 μg | EUR 537.84 |
Peptide 34 / GPR-54 Agonist |
|||
048-94 | PHOENIX PEPTIDE | 200 μg | EUR 114.48 |
FGL Peptide - I-125 Labeled |
|||
T-073-36 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Peptide-Depleted Plasma (Human) |
|||
MB-099-01 | PHOENIX PEPTIDE | 2 ml | EUR 119.88 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - FAM Labeled |
|||
FG-064-07A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - I-125 Labeled |
|||
T-064-01 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
F3 Peptide / HMGN2 Fragment 3 |
|||
004-12 | PHOENIX PEPTIDE | 100 μg | EUR 214.92 |
Myosin Kinase Inhibiting Peptide |
|||
058-20 | PHOENIX PEPTIDE | 500 μg | EUR 50.76 |
Antimicrobial Trp-rich peptide |
|||
004-05 | PHOENIX PEPTIDE | 100 μg | EUR 140.4 |
Fibronectin CS1 Peptide (EILDVPST) |
|||
025-20 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Peptide YY (PYY) (3-36) (Human) |
|||
059-02 | PHOENIX PEPTIDE | 200 μg | EUR 102.6 |
Peptide YY (PYY) (Human) - Antibody |
|||
H-059-01 | PHOENIX PEPTIDE | 100 μl | EUR 469.8 |
PGMtide Peptide - Rhodamine Labeled |
|||
FR-040-69 | PHOENIX PEPTIDE | 5 nmol | EUR 604.8 |
Anti-Angiogenic Peptide Library |
|||
L-008A | PHOENIX PEPTIDE | 88 peptides | EUR 6067.44 |
Peptide Histidine Isoleucine 27 (PHI-27) / Porcine Intestinal Peptide (Porcine) - Purified IgG Antibody |
|||
G-064-01 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Peptide A / p60v-src (137-157) |
|||
058-21 | PHOENIX PEPTIDE | 500 μg | EUR 135 |
pro-Opionmelanocortin / J Peptide |
|||
022-22 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Cancer-Targeting Peptide Library |
|||
L-015 | PHOENIX PEPTIDE | 289 peptides | EUR 7253.28 |
C28 optimized peptide 6 (Human) |
|||
073-82 | PHOENIX PEPTIDE | 100 μg | EUR 235.44 |
Peptide YY (PYY) (Human) - EIA Kit |
|||
EK-059-01 | PHOENIX PEPTIDE | 96 wells | EUR 617.76 |
Peptide YY (PYY) (Human) - RIA Kit |
|||
RK-059-01 | PHOENIX PEPTIDE | 125 tubes | EUR 814.32 |
Kemptide / Phosphate Acceptor Peptide |
|||
058-16 | PHOENIX PEPTIDE | 500 μg | EUR 36.72 |
Bioactive Secretory Peptide Library |
|||
L-009 | PHOENIX PEPTIDE | 1016 peptides | EUR 31350.24 |
PACAP-Related Peptide (PRP) (Rat) |
|||
052-11 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Galanin-Like Peptide (GALP) (Rat) |
|||
026-52 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - I-125 Labeled |
|||
T-064-07 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Virus Replication Inhibiting Peptide |
|||
070-85 | PHOENIX PEPTIDE | 5 mg | EUR 160.92 |
Crustacean Cardioactive Peptide (CCAP) |
|||
047-24 | PHOENIX PEPTIDE | 500 μg | EUR 86.4 |
Pri Peptide from sORF pri RNA |
|||
069-77 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Alzheimer Fingerprint Peptide Library |
|||
L-011 | PHOENIX PEPTIDE | 85 peptides | EUR 6529.68 |
PACAP-Related Peptide (PRP) (Human) |
|||
052-10 | PHOENIX PEPTIDE | 200 μg | EUR 86.4 |
Scrambled Control for Pri Peptide |
|||
069-78 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
FMRF-Like Peptide (Helix aspersa) |
|||
047-31 | PHOENIX PEPTIDE | 1 mg | EUR 27 |
Annexin A1 Binding Peptide, IF7CRR |
|||
025-72 | PHOENIX PEPTIDE | 200 μg | EUR 184.68 |
Galanin-Like Peptide (GALP) (Human) |
|||
026-51 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Rat) |
|||
027-32 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
u PAR (84-95) Scrambled Peptide |
|||
072-47 | PHOENIX PEPTIDE | 200 μg | EUR 177.12 |
Kinetensin / Neurotensin Related Peptide |
|||
048-01 | PHOENIX PEPTIDE | 500 μg | EUR 58.32 |
Small Cardioactive Peptide A (SCPA) |
|||
047-76 | PHOENIX PEPTIDE | 1 mg | EUR 64.8 |
Gastrin Releasing Peptide (GRP) (Frog) |
|||
027-33 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
Epidermal Growth Factor Receptor Peptide (985-996) |
|||
030-05 | PHOENIX PEPTIDE | 500 μg | EUR 102.6 |
Peptide Histidine Methionine 27 (PHM-27) / Peptide Histidine Isoleucine (PHI) (Human) - Purified IgG Antibody |
|||
G-064-07 | PHOENIX PEPTIDE | 400 μg | EUR 438.48 |
Galanin-Like Peptide (GALP) (Porcine) |
|||
026-50 | PHOENIX PEPTIDE | 100 μg | EUR 230.04 |
Gastrin Releasing Peptide (GRP) (Human) |
|||
027-07 | PHOENIX PEPTIDE | 200 μg | EUR 119.88 |
Gastrin Releasing Peptide (GRP) (Mouse) |
|||
027-40 | PHOENIX PEPTIDE | 100 μg | EUR 160.92 |
PGMtide Control Peptide - Cy3 Labeled |
|||
FC3-040-70 | PHOENIX PEPTIDE | 1 nmol | EUR 925.56 |
PGMtide Control Peptide - FAM Labeled |
|||
FG-040-70A | PHOENIX PEPTIDE | 5 nmol | EUR 537.84 |
Growth Blocking Peptide - FAM Labeled |
|||
FG-046-92A | PHOENIX PEPTIDE | 1 nmol | EUR 336.96 |
Chop-Suey / Variety Peptide Library |
|||
L-001 | PHOENIX PEPTIDE | 238 peptides | EUR 7400.16 |
T3 Peptide / Tumstatin (69-88) (Human) |
|||
016-50 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
T7 Peptide / Tumstatin (74-98) (Human) |
|||
016-51 | PHOENIX PEPTIDE | 100 μg | EUR 255.96 |
Peptide YY (PYY) (1-36)-Gly (Human) |
|||
059-07 | PHOENIX PEPTIDE | 100 μg | EUR 295.92 |
Peptide YY (PYY) (3-36)-Gly (Human) |
|||
059-08 | PHOENIX PEPTIDE | 100 μg | EUR 282.96 |
Peptide YY (PYY) (2-36)-Gly (Human) |
|||
059-11 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Peptide YY (PYY) (4-36)-Gly (Human) |
|||
059-12 | PHOENIX PEPTIDE | 100 μg | EUR 267.84 |
Hypocholesterolemic Peptide / IIAEK (Bovine) |
|||
028-37 | PHOENIX PEPTIDE | 500 μg | EUR 177.12 |
Fractalkine Chemokine Domain peptide (41-52) (Human) |
|||
026-82 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
Fractalkine Chemokine Domain peptide (53-60) (Human) |
|||
026-83 | PHOENIX PEPTIDE | 200 μg | EUR 135 |
Fractalkine Chemokine Domain peptide (60-71) (Human) |
|||
026-84 | PHOENIX PEPTIDE | 200 μg | EUR 160.92 |
FMRF-Like Peptide ( Lymnae stagnalis) |
|||
047-30 | PHOENIX PEPTIDE | 5 mg | EUR 129.6 |
Peptide F (Bovine) - I-125 Labeled |
|||
T-024-58 | PHOENIX PEPTIDE | 10 μCi | EUR 1145.88 |
Delta-Sleep-Inducing Peptide (DSIP) |
|||
070-22 | PHOENIX PEPTIDE | 500 μg | EUR 27 |
[Thr5]-Speract / Sperm Activating Peptide |
|||
070-71 | PHOENIX PEPTIDE | 1 mg | EUR 114.48 |
Kappa-Receptor, C-terminal peptide |
|||
002-98 | PHOENIX PEPTIDE | 100 μg | EUR 469.8 |
Angiotensin II - constrained peptide 1 |
|||
004-09 | PHOENIX PEPTIDE | 500 μg | EUR 165.24 |
The equivalent calculation of dissolved methane is also presented as a benchmark for comparison. This study calls for reassessing troops that stabilize the conformation of proteins folded in aqueous solution and additives of hydrophobic / hydrophilic contributions.